Chenodiol

Chenodiol

SCHEMBL209535

C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

NR1H4

The experimentally established mechanism targets of Chenodiol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NR1H4 known ✓ Q96RI1 7/20 1.00
GPBAR1 Q8TDU6 14/20 1.00
ABCB11 O95342 3/20 1.00
MEN1 O00255 2/20 1.00
KMT2A Q03164 2/20 1.00
SLC10A2 Q12908 2/20 1.00
ENPP2 Q13822 2/20 1.00
CYP3A4 P08684 2/20 1.00
LMNA P02545 1/20 1.00
CYP2C19 P33261 1/20 1.00
CHRM2 P08172 1/20 1.00
ADRA2A P08913 1/20 1.00
ADRA1A P35348 1/20 1.00
TDP1 Q9NUW8 1/20 1.00
SLC10A1 Q14973 1/20 1.00
CISD1 Q9NZ45 1/20 1.00
PDE3A Q14432 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Chenodiol SCHEMBL22079588 1.00 GPBAR1 (1.00) GPBAR1NR1H4ABCB11MEN1KMT2A
Chenodiol SCHEMBL24199134 1.00 GPBAR1 (1.00) GPBAR1NR1H4ABCB11MEN1KMT2A
Chenodiol SCHEMBL23517166 1.00 GPBAR1 (1.00) GPBAR1NR1H4ABCB11MEN1KMT2A
Chenodiol SCHEMBL22079179 1.00 GPBAR1 (1.00) GPBAR1NR1H4ABCB11MEN1KMT2A
Chenodiol SCHEMBL25337643 1.00 GPBAR1 (1.00) GPBAR1NR1H4ABCB11MEN1KMT2A
Chenodiol SCHEMBL24124587 1.00 GPBAR1 (1.00) GPBAR1NR1H4ABCB11MEN1KMT2A
Chenodiol SCHEMBL25397934 1.00 GPBAR1 (1.00) GPBAR1NR1H4ABCB11MEN1KMT2A
Chenodiol SCHEMBL24061005 1.00 GPBAR1 (1.00) GPBAR1NR1H4ABCB11MEN1KMT2A
Chenodiol SCHEMBL23704676 1.00 GPBAR1 (1.00) GPBAR1NR1H4ABCB11MEN1KMT2A
Chenodiol SCHEMBL25337648 1.00 GPBAR1 (1.00) GPBAR1NR1H4ABCB11MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3869192-B1 METHOD FOR QUANTITATIVE DETECTION OF VARIOUS METABOLITES IN BIOLOGICAL SAMPLE HUMAN METABOLOMICS INST INC (CN) 2026-05-13 EP claimed
US-20250258146-A1 QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP HUMAN METABOLOMICS INSTITUTE INC. (CN) 2025-08-14 US claimed
EP-4537111-A2 MULTI-OMICS ASSESSMENT Prognomiq Inc (US) 2025-04-16 EP claimed
CN-119816897-A Multiple study assessment 普罗科技有限公司 2025-04-11 CN claimed
CN-116396349-B Method for purifying isoursodeoxycholic acid 常德云港生物科技股份有限公司 2024-09-13 CN claimed
US-20240263251-A1 COMPOSITIONS AND METHODS FOR PROVIDING SECONDARY BILE ACIDS TO A SUBJECT FINCH THERAPEUTICS HOLDINGS LLC (US) 2024-08-08 US claimed
EP-4386090-A1 METHOD FOR DETERMINING AND IMPROVING THE POTENTIAL EFFICACY OF ANTICANCER TREATMENT ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (FR) 2024-06-19 EP claimed
US-20240183845-A1 BILE ACID METABOLITES FOR DIAGNOSING AND TREATING DEPRESSIVE DISORDERS KADDURAH DAOUK RIMA F (US) 2024-06-06 US claimed
WO-2023240046-A2 MULTI-OMICS ASSESSMENT PrognomIQ, Inc. (US) 2023-12-14 WO claimed
US-20230375534-A1 MEANS AND METHODS TO DIAGNOSE GUT FLORA DYSBIOSIS AND INFLAMMATION VIB VZW (BE) 2023-11-23 US claimed
US-6627197-B2 Using variant of a protein synthesis inactivating toxin wherein a viral protease cleavage site is interposed between A and B chains; treatment of human immunodeficiency virus BECHTEL BWXT IDAHO, LLC 2003-09-30 US claimed
US-6589943-B2 Made by dissolving an amphiphilic heparin derivative comprising heparin conjugated to bile acids, sterols, or alkanoic acids in a water phase, dispersing the water phase in an organic phase to form an emulsion, drying the emulsion MEDIPLEX CORPORATION, KOREA (KR) 2003-07-08 US claimed
WO-2003004685-A2 SOLUBLE STEROIDAL PEPTIDES FOR NUCLEIC ACID DELIVERY UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2003-01-16 WO claimed
WO-2002089820-A1 FORMULATION OF AMPHIPHILIC HEPARIN DERIVATIVES FOR ENHANCING MUCOSAL ABSORPTION MEDIPLEX CORPORATION (KR) 2002-11-14 WO claimed
US-20020094334-A1 Selective destruction of cells infected with human immunodeficiency virus BATTELLE ENERGY ALLIANCE, LLC 2002-07-18 US claimed
US-20020013292-A1 Formulation of amphiphilic heparin derivatives for enhancing mucosal absorption MEDIPLEX CORPORATION KOREA (KR) 2002-01-31 US claimed
US-20020010153-A1 Oral delivery of macromolecules MEDIPLEX CORPORATION (KR) 2002-01-24 US claimed
WO-2001060393-A1 SELECTIVE DESTRUCTION OF CELLS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS BECHTEL BWXT IDAHO, LLC (US) 2001-08-23 WO claimed
US-6245753-B1 Amphiphilic polysaccharide derivatives MEDIPLEX CORPORATION, KOREA (KR) 2001-06-12 US claimed
WO-1999061481-A1 AMPHIPHILIC POLYSACCHARIDE DERIVATIVES MEDIPLEX CORPORATION, KOREA (KR) 1999-12-02 WO claimed